ClinVar

Description

p.Met1906Thr (ATG>ACG): c.5717 T>C in exon 38 of the RYR2 gene (NM_001035.2). The Met1906Thr variant in the RYR2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Met1906Thr results in a non-conservative amino acid substitution of a non-polar Methionine residue with a polar Threonine residue at a position that is conserved across species. In silico analysis predicts Met1906Thr is probably damaging to the protein structure/function. Also, the NHLBI ESP Exome Variant Server reports Met1906Thr was not observed in approximately 6,000 samples from individuals of European and African American backgrounds, indicating it is not a common benign variant in these populations. Nevertheless, no mutations in nearby codons have been reported in association with ARVC or an RYR2-related phenotype, indicating this region of the protein may be tolerant of change. With the clinical and molecular information available at this time, we cannot definitively determine if Met1906Thr is a disease-causing mutation or a rare benign variant. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is primarily an autosomal dominant disease characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death (McNally E et al., 2009; Nava A et al., 2000). ARVC is most frequently caused by mutations in the genes encoding desmosomal proteins, complexes that maintain cell-to-cell connections and provide mechanical attachments among adjacent cells. Less commonly, ARVC may be caused by mutations in genes that encode proteins that maintain calcium homeostasis (McNally E et al., 2009). Approximately 50% of patients with autosomal dominant CPVT have been reported to have a mutation in the RYR2 gene, while mutations in the RYR2 gene associated with ARVC are rare (McNally E et al., 2009; Napolitano C et al., 2012). The variant is found in ARVC panel(s).